Journal
EUROPEAN UROLOGY FOCUS
Volume 4, Issue 4, Pages 481-484Publisher
ELSEVIER
DOI: 10.1016/j.euf.2018.06.018
Keywords
Bacillus Calmette-Guerin; Shortage; Bladder cancer
Categories
Ask authors/readers for more resources
Bacillus Calmette-Guerin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive bladder cancer. Primary producers of BCG announced shortages within the last decade, leading to a worldwide shortage. We review the literature examining the BCG shortage and propose solutions to cope with this problem. (C) 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available